ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) has been assigned an average rating of “Buy” from the seven brokerages that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation, three have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $6.17.
Several equities research analysts have weighed in on ZIOP shares. Laidlaw started coverage on ZIOPHARM Oncology in a research report on Monday. They issued a “buy” rating and a $7.50 target price on the stock. BidaskClub lowered ZIOPHARM Oncology from a “buy” rating to a “hold” rating in a research report on Saturday, December 15th. Finally, Zacks Investment Research raised ZIOPHARM Oncology from a “hold” rating to a “buy” rating and set a $3.75 target price on the stock in a research report on Friday, December 7th.
A number of hedge funds and other institutional investors have recently modified their holdings of ZIOP. Alliancebernstein L.P. grew its stake in shares of ZIOPHARM Oncology by 18.6% in the third quarter. Alliancebernstein L.P. now owns 277,830 shares of the biotechnology company’s stock worth $889,000 after purchasing an additional 43,611 shares in the last quarter. BlackRock Inc. grew its stake in shares of ZIOPHARM Oncology by 1.3% in the third quarter. BlackRock Inc. now owns 9,289,620 shares of the biotechnology company’s stock worth $29,727,000 after purchasing an additional 121,880 shares in the last quarter. FMR LLC bought a new position in shares of ZIOPHARM Oncology in the third quarter worth $1,647,000. Jefferies Group LLC grew its stake in shares of ZIOPHARM Oncology by 100.8% in the third quarter. Jefferies Group LLC now owns 96,972 shares of the biotechnology company’s stock worth $310,000 after purchasing an additional 48,685 shares in the last quarter. Finally, Jane Street Group LLC bought a new position in shares of ZIOPHARM Oncology in the third quarter worth $161,000. 38.01% of the stock is currently owned by hedge funds and other institutional investors.
ZIOPHARM Oncology Company Profile
ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells.
Further Reading: How Do Tariffs Affect Trade Balances?
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.